Innocent Information

Creative Biolabs Launched High-quality Auristatin ADCs with Appropriate Linkers

As a biotechnology company highly specialized in designing and creating ADCs, Creative Biolabs recently has launched high-quality auristatin ADCs with appropriate linkers using the advanced “DrugLnk” research platform in order to meet every client’s unique requirements.

As a biotechnology company highly specialized in designing and creating ADCs, Creative Biolabs recently has launched high-quality auristatin ADCs with appropriate linkers using the advanced “DrugLnk” research platform in order to meet every client’s unique requirements.

Auristatins are a family of complex analogues to the native antineoplastic product dolastatin 10. They are 100 to 1000 times more toxic than Doxorubicin, a conventional cancer chemotherapy medication. Therefore, as a result of their high cytotoxicity, harmful side-effects and a narrow therapeutic window were reported in clinical trials of auristatins, rendering them unsuitable as anticancer medications.

“Fortunately, scientists finally get over the high cytotoxicity of auritatins by removing one methyl group at the N-terminus of dolavaline, giving rise to a series of auristatin analogues with only slightly decreased potency. Those new auristatins contain a secondary amine at their N-termini that enables their coupling with a linker and subsequent conjugation to monoclonal antibodies,” said Dr. Monika Müller, Scientific Officer of Creative Biolabs.

“For example, Brentuximab vedotin is an ADC composed of an auristatin analog, monomethylauristatin-E (MMAE) conjugated to an anti-CD30 Ab through a protease cleavable linker. This ADC can bring about continuous positive responses in suppressing tumor regression in majority of patients with relapsed or refractory CD30+ lymphomas. Currently, several auristatin analogous have been deployed as ADC payloads in clinical trials, including MMAF and a newly developed dolastatin 10 analogue PF-06380101.”

At this moment, an increasing number of auristatin analogues are being synthesized and the application of auristatin derivatives will become one of the cornerstones for ADC development. With a professional team and an advanced platform, Creative Biolabs can provide global clients with tailored peptide ligands, optimized linkers and suitable conjugation strategies to meet your demand.

About Creative Biolabs

Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, preclinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world. 

Media Contact
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: http://www.creativebiolabs.net

Calendar

February 2018
M T W T F S S
« Jan    
 1234
567891011
12131415161718
19202122232425
262728